Hints and tips:
...But after enrolling in a trial of an experimental therapy developed by Eli Lilly, the 65-year-old former teacher says her memory has improved and she is able to do things she previously found difficult....
...Kirin Holdings said last week that it would withdraw from its business in Myanmar in an effort to end its two joint ventures with military-linked partner Myanma Economic Holdings Ltd....
...US pharmaceutical company Eli Lilly said it would apply for approval of its medicine, donanemab, by the end of this year, an announcement that sent its shares up 9 per cent....
...There an entrepreneur named Eli Broad was taking his quieter financial revolution to the suburbs. In time, it would become Rowan’s model....
...This morning, those at Capita – and those still holding its shares – got an answer....
...Ocean’s quest to turn cash-rich Bowleven into a holding company and return excess money to shareholders....
...We are always looking to improve so drop us a line if you have a thought: Due.Diligence@ft.com Baby, even the losers Loss aversion — the idea of holding on to garbage investments to avoid the reckoning...
...Previous non-executive roles include at the Bank of China, Singapore Airlines and the NYSE Euronext group and he will continue current non-executive directorships at Eli Lilly, the US drugmaker, MasterCard...
...Another drug called fruquintinib for colorectal cancer, co-developed with Eli Lilly, is also in late-stage development and five others are in earlier stage clinical trials....
...Gradually, however, China MediTech, or Chi-Med, began building its own R&D capabilities in partnership with western drugmakers including Eli Lilly and AstraZeneca....
...After 3,400 of those comment letters had rolled into the DoL, most critical of some or all of the new rules, Jon Stein and Eli Broverman, Betterment’s founders, fired off a letter of their own....
...Chi-Med is a subsidiary of Mr Li’s Hutchison Whampoa group and its holding company is listed on London’s junior Aim stock exchange....
...An FDA warning was eventually issued but Takeda and Eli Lilly, which marketed the drug in the US, say the cancer link remains unproved....
...(Financial Times) “A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in punitive damages and Eli Lilly and Co to pay $3 billion in a case claiming that cancer risks to the diabetes drug...
...Eli Lilly, the US drugmaker, last year withdrew sepsis treatment Xigris from the market after trials showed that it failed to cut the mortality rate in patients with septic shock....
...It also has partnerships with the likes of Novartis, Roche, Merck and Eli Lilly that it hopes to build on....
...Among large-scale deals, the “pure” research and development companies led by AstraZeneca and Eli Lilly appear among the most vulnerable....
...Eli Lederman, who ran the Turquoise share trading platform before it was bought by the LSE in February 2010, took the company to an employment tribunal in London in March arguing that he was entitled to...
...The exchange said on the opening day of the case it would not contest a charge brought by Eli Lederman, who ran the Turquoise share trading platform before it was bought by the LSE little more than a year...
...The companies selected, based on the largest spenders of research and development funds in 2008-09, were Pfizer, Roche, Novartis, Sanofi-Aventis, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Merck, Eli...
...Improve R&D As John Lechleiter, head of Eli Lilly, put it recently: “At a time when the world desperately needs more new medicines …we’re taking too long, spending too much and producing far too little....
...Abbott Laboratoriesfell 1.3 per cent to $51.12, Johnson & Johnson was 0.9 per cent lower at $64.78 and Eli Lilly lost 1.8 per cent to $35.38....
...Arm Holdings led the fallers, down 1.7 per cent to 254½p, having been lifted this week by dubious talk of bid interest....
...Drug company Eli Lilly reported earnings that were better than both the same period last year and estimates for this period, but its shares lost 2.3 per cent to $32.99 as investors worried about weaker...
...Oh, and also, if you’re a company director, don’t pledge company holdings as loan collateral, a la David Ross....
International Edition